Here are five things to know:
1. Canaccord Genuity presently has a target price of $108.00 on Stryker’s stock, thus indicative of a potential upside of 13.56 percent from the Stryker’s current price.
2. On Friday, May 22, Zacks’ analysts upgraded Stryker stocks from a “hold” rating to a “buy” rating. The analysts set a $108.00 price target on the stock in a research note.
3. Stryker currently has an average rating of “buy” and a consensus target price of $99.47.
4. Ronda Stryker, director of the company, sold 12,000 shares this past Wednesday for a total transaction of $1,135,320.00. Each share sold at an average price of $94.61.
5. On Tuesday, April 21, Stryker announced its earnings, reporting $1.11 earnings per share for the quarter, surpassing the consensus estimate of $1.08 by $0.03.
For more news:
American Society of Regional Anesthesia and Acute Pain Medicine Meeting — 3 presentations to know
$55k is the average medical resident salary — 8 key statistics
7 statistics on the PPACA & physician practices
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
